NCT04484948

Brief Summary

This study aims to evaluate the utility of breath-holding test as a marker of pulmonary disease severity in patients with systemic sclerosis.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
120

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Aug 2020

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 21, 2020

Completed
3 days until next milestone

First Posted

Study publicly available on registry

July 24, 2020

Completed
19 days until next milestone

Study Start

First participant enrolled

August 12, 2020

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 29, 2021

Completed
2.3 years until next milestone

Study Completion

Last participant's last visit for all outcomes

May 31, 2023

Completed
Last Updated

June 2, 2023

Status Verified

May 1, 2023

Enrollment Period

6 months

First QC Date

July 21, 2020

Last Update Submit

May 31, 2023

Conditions

Keywords

Breath-holding testSix minute walk testSystemic sclerosis

Outcome Measures

Primary Outcomes (1)

  • Correlation of breath-holding test with Borg Dyspnea Index

    Borg Scale on a 0-10 point

    Day 1 at inclusion

Secondary Outcomes (5)

  • Correlation of breath-holding time with 6 minute walk test (6MWT) distance

    Day 1 at inclusion

  • Correlation of breath-holding time with oxygen saturation during 6MWT

    Day 1 at inclusion

  • Correlation of breath-holding time with pulmonary function indices

    Day 1 at inclusion

  • Correlation of breath-holding time with data on the echocardiography

    Day 1 at inclusion

  • Correlation of breath-holding time with scleroderma health assessment questionnaire (SHAQ)

    Day 1 at inclusion

Other Outcomes (5)

  • Changes of oxygen saturation during breath-holding test

    Day 1 at inclusion

  • Changes of oxygen saturation during of 6MWT

    Day 1 at inclusion

  • Responsiveness of breath-holding test

    Month 6 at inclusion

  • +2 more other outcomes

Study Arms (1)

Systemic sclerosis group

EXPERIMENTAL

Systemic sclerosis diagnosis according to 2013 American College of Rheumatology(ACR)/European League Against Rheumatism(EULAR) classification criteria

Other: scleroderma health assessment questionnaire (SHAQ), BHT, and 6MWT

Interventions

1. Participants will perform the SHAQ. 2. BHT and 6MWT will be performed in the randomized way for each participant. 3. For BHT, the participants will be told to sit comfortably on a chair, and breath normally. After 1 minute, they were required to make a maximum expiration followed by a maximum inspiration and to hold the breath as long as possible at maximum inspiratory level. This procedure was repeated three times, with 5-minute intervals between the tests. 4. 6MWT will be performed according to the ATS guidelines. 5. Information on CXR, TTE, and PFT (FVC%, DLCO%) will be obtained from the medical record if the data was obtained within 3 months. If not, the tests will be performed. 6. BHT and PFT will be followed by six months after the first breath-holding test to confirm the responsiveness. 7. Additional 30 patients with systemic sclerosis will be collected to perform the test-retest reliability of BHT.

Systemic sclerosis group

Eligibility Criteria

Age19 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • A diagnosis of systemic sclerosis according to 2013 ACR/EULAR criteria
  • Must understand and voluntarily sign an informed consent form including writing consent for data protection

You may not qualify if:

  • The resting oxygen saturation by pulse oximetry \< 90% in room air
  • Unstable angina or myocardial infarction during the previous month
  • Patients considered unable to the breath-holding test or 6 minute walk test

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Seoul National University Hospital

Seoul, 03080, South Korea

Location

Related Publications (6)

  • Hachulla E, Launay D. Diagnosis and classification of systemic sclerosis. Clin Rev Allergy Immunol. 2011 Apr;40(2):78-83. doi: 10.1007/s12016-010-8198-y.

    PMID: 20143182BACKGROUND
  • Morelli S, Ferrante L, Sgreccia A, Eleuteri ML, Perrone C, De Marzio P, Balsano F. Pulmonary hypertension is associated with impaired exercise performance in patients with systemic sclerosis. Scand J Rheumatol. 2000;29(4):236-42. doi: 10.1080/030097400750041389.

    PMID: 11028845BACKGROUND
  • Vandecasteele E, De Pauw M, De Keyser F, Decuman S, Deschepper E, Piette Y, Brusselle G, Smith V. Six-minute walk test in systemic sclerosis: A systematic review and meta-analysis. Int J Cardiol. 2016 Jun 1;212:265-73. doi: 10.1016/j.ijcard.2016.03.084. Epub 2016 Mar 25.

    PMID: 27057932BACKGROUND
  • Impens AJ, Wangkaew S, Seibold JR. The 6-minute walk test in scleroderma--how measuring everything measures nothing. Rheumatology (Oxford). 2008 Oct;47 Suppl 5:v68-9. doi: 10.1093/rheumatology/ken273.

    PMID: 18784152BACKGROUND
  • ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002 Jul 1;166(1):111-7. doi: 10.1164/ajrccm.166.1.at1102. No abstract available.

    PMID: 12091180BACKGROUND
  • Yeo J, Kim JY, Kim MH, Park JW, Park JK, Lee EB. Utility of the breath-holding test in patients with systemic sclerosis. Rheumatology (Oxford). 2022 Oct 6;61(10):4113-4118. doi: 10.1093/rheumatology/keac020.

Related Links

MeSH Terms

Conditions

Scleroderma, Systemic

Interventions

Butylated Hydroxytoluene

Condition Hierarchy (Ancestors)

Connective Tissue DiseasesSkin and Connective Tissue DiseasesSkin Diseases

Intervention Hierarchy (Ancestors)

CresolsPhenolsBenzene DerivativesHydrocarbons, AromaticHydrocarbons, CyclicHydrocarbonsOrganic Chemicals

Study Officials

  • Eun Bong Lee, MD PhD

    Seoul National University College of Medicine

    PRINCIPAL INVESTIGATOR
  • Jina Yeo, MD

    Seoul National University College of Medicine

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
OTHER
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

July 21, 2020

First Posted

July 24, 2020

Study Start

August 12, 2020

Primary Completion

January 29, 2021

Study Completion

May 31, 2023

Last Updated

June 2, 2023

Record last verified: 2023-05

Locations